Profiling the molecular mechanism of fullerene cytotoxicity on tumor cells by RNA-seq

Toxicology

Volumn 314, Issue 1, 2013, Pages 183-192

  Lucafò, Marianna ^a   Gerdol, Marco ^a   Pallavicini, Alberto ^a   Pacor, Sabrina ^a   Zorzet, Sonia ^a   Da Ros, Tatiana ^a   Prato, Maurizio ^a   Sava, Gianni ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Fullerene; Gene expression; Nanotoxicology; Next generation sequencing; RNA seq

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; FULLERENE 1; FULLERENE 2; FULLERENE DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN; NANOMATERIAL; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DNA; RNA; TARGET OF RAPAMYCIN KINASE; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BEHAVIOR CHANGE; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; BREAST CARCINOMA; CANCER CELL CULTURE; CARCINOMA CELL; CELL ADHESION; CELL CYCLE G0 PHASE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG SAFETY; ENZYME INHIBITION; ENZYME MECHANISM; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RNA SEQUENCE; UPREGULATION; CELL CYCLE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; PHYSIOLOGY; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TOXICITY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; DNA; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; EXTRACELLULAR MATRIX; FULLERENES; G0 PHASE; GENE EXPRESSION; HUMANS; NANOSTRUCTURES; NEOPLASM PROTEINS; RNA; SEQUENCE ANALYSIS, RNA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 84886994567     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2013.10.001     Document Type: Article

References (58)

1. Aardema M., MacGregor J. Toxicology and genetic toxicology in the New Era of "Toxicogenomics": impact of "-omics" technologies. Toxicogenomics 2003, 171-193. Springer, Japan. T. Inoue, W. Pennie (Eds.).
2. Adolph S., Brusselbach S., Muller R. Inhibition of transcription blocks cell cycle progression of NIH3T3 fibroblasts specifically in G1. J. Cell Sci. 1993, 105:113-122.
3. Alayev A., Holz M.K. mTOR signaling for biological control and cancer. J. Cell. Physiol. 2013, 228:1658-1664.
4. Al-Shahrour F., Minguez P., Vaquerizas J.M., Conde L., Dopazo J. BABELOMICS: a suite of web tools for functional annotation and analysis of groups of genes in high-throughput experiments. Nucleic Acids Res. 2005, 33:W460-W464.
5. Blomme E.A.G., Yang Y., Waring J.F. Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development. Toxicol. Lett. 2009, 186:22-31.
6. Boverhof D.R., Zacharewski T.R. Toxicogenomics in risk assessment: applications and needs. Toxicol. Sci. 2006, 89:352-360.
7. Brugarolas J., Lei K., Hurley R.L., Manning B.D., Reiling J.H., Hafen E., Witters L.A., Ellisen L.W., Kaelin W.G. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004, 18:2893-2904.
8. Cagle D.W., Kennel S.J., Mirzadeh S., Alford J.M., Wilson L.J. In vivo studies of fullerene-based materials using endohedral metallofullerene radiotracers. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:5182-5187.
9. Cui Y., Paules R.S. Use of transcriptomics in understanding mechanisms of drug-induced toxicity. Pharmacogenomics 2010, 11:573-585.
10. DeYoung M.P., Horak P., Sofer A., Sgroi D., Ellisen L.W. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 2008, 22:239-251.
11. Falcon S., Gentleman R. Using GOstats to test gene lists for GO term association. Bioinformatics 2007, 23:257-258.
12. Fonseca B.D., Diering G.H., Bidinosti M.A., Dalal K., Alain T., Balgi A.D., Forestieri R., Nodwell M., Rajadurai C.V., Gunaratnam C., Tee A.R., Duong F., Andersen R.J., Orlowski J., Numata M., Sonenberg N., Roberge M. Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling. J. Biol. Chem. 2012, 287:17530-17545.
13. Foster D.A., Yellen P., Xu L., Saqcena M. Regulation of G1 cell cycle progression: distinguishing the restriction point from a nutrient-sensing cell growth checkpoint(s). Genes Cancer 2010, 1:1124-1131.
14. 60 fullerene particles. Toxicology 2009, 258:47-55.
15. Gao J., Wang H.L., Shreve A., Iyer R. Fullerene derivatives induce premature senescence: a new toxicity paradigm or novel biomedical applications. Toxicol. Appl. Pharmacol. 2010, 244:130-143.
16. Geng Y., Weinberg R.A. Transforming growth factor β effects on expression of G1 cyclins and cyclin-dependent protein kinases. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:10315-10319.
17. Ghayad S.E., Bieche I., Vendrell J.A., Keime C., Lidereau R., Dumontet C., Cohen P.A. mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008, 99:1992-2003.
18. Guo X., Wang X.-F. Signaling cross-talk between TGF-[beta]/BMP and other pathways. Cell Res. 2009, 19:71-88.
19. Gwinn D.M., Shackelford D.B., Egan D.F., Mihaylova M.M., Mery A., Vasquez D.S., Turk B.E., Shaw R.J. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 2008, 30:214-226.
20. Hancock D.E., Indest K.J., Gust K.A., Kennedy A.J. Effects of C 60 on the Salmonella typhimurium TA100 transcriptome expression: insights into C 60-mediated growth inhibition and mutagenicity. Environ. Toxicol. Chem. 2012, 31:1438-1444.
21. He X., Zhu Z., Johnson C., Stoops J., Eaker A.E., Bowen W., DeFrances M.C. PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma. Cancer Res. 2008, 68:5591-5598.
22. Horne M.C., Donaldson K.L., Goolsby G.L., Tran D., Mulheisen M., Hell J.W., Wahl A.F. Cyclin G2 is up-regulated during growth inhibition and B cell antigen receptor-mediated cell cycle arrest. J. Biol. Chem. 1997, 272:12650-12661.
23. Huang S., Chakrabarty S. Regulation of fibronectin and laminin receptor expression, fibronectin and laminin secretion in human colon cancer cells by transforming growth factor-β1. Int. J. Cancer 1994, 57:742-746.
24. Huang J., Manning B.D. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem. Soc. Trans. 2009, 37:217-222.
25. Hyytiäinen M., Keski-Oja J. Latent TGF-β binding protein LTBP-2 decreases fibroblast adhesion to fibronectin. J. Cell Biol. 2003, 163:1363-1374.
26. Ishii I., Harada Y., Kasahara T. Reprofiling a classical anthelmintic, pyrvinium pamoate, as an anti-cancer drug targeting mitochondrial respiration. Front. Oncol. 2012, 2.
27. Jovanović B., Ji T., Palić D. Gene expression of zebrafish embryos exposed to titanium dioxide nanoparticles and hydroxylated fullerenes. Ecotoxicol. Environ. Saf. 2011, 74:1518-1525.
28. Kal A.J., van Zonneveld A.J., Benes V., van den Berg M., Koerkamp M.G., Albermann K., Strack N., Ruijter J.M., Richter A., Dujon B., Ansorge W., Tabak H.F. Dynamics of gene expression revealed by comparison of serial analysis of gene expression transcript profiles from yeast grown on two different carbon sources. Mol. Biol. Cell 1999, 10:1859-1872.
29. Kang S., Dong S., Kim B.-R., Park M., Trink B., Byun H.-J., Rho S. Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells. Apoptosis 2012, 17:989-997.
30. Kantola A.K., Keski-Oja J., Koli K. Fibronectin and heparin binding domains of latent TGF-β binding protein (LTBP)-4 mediate matrix targeting and cell adhesion. Exp. Cell Res. 2008, 314:2488-2500.
31. Karkoulis P., Stravopodis D., Konstantakou E., Voutsinas G. Targeted inhibition of heat shock protein 90 disrupts multiple oncogenic signaling pathways, thus inducing cell cycle arrest and programmed cell death in human urinary bladder cancer cell lines. Cancer Cell Int. 2013, 13:11.
32. Kirken R.A., Wang Y.L. Molecular actions of sirolimus: sirolimus and mTor. Transplant. Proc. 2003, 35:227S-230S.
33. Lamb J., Crawford E.D., Peck D., Modell J.W., Blat I.C., Wrobel M.J., Lerner J., Brunet J.-P., Subramanian A., Ross K.N., Reich M., Hieronymus H., Wei G., Armstrong S.A., Haggarty S.J., Clemons P.A., Wei R., Carr S.A., Lander E.S., Golub T.R. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313:1929-1935.
34. Lamouille S., Connolly E., Smyth J.W., Akhurst R.J., Derynck R. TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J. Cell Sci. 2012, 125:1259-1273.
35. Li W., Zhao L., Wei T., Zhao Y., Chen C. The inhibition of death receptor mediated apoptosis through lysosome stabilization following internalization of carboxyfullerene nanoparticles. Biomaterials 2011, 32:4030-4041.
36. Lucafò M., Pacor S., Fabbro C., Da Ros T., Zorzet S., Prato M., Sava G. Study of a potential drug delivery system based on carbon nanoparticles: effects of fullerene derivatives in MCF7 mammary carcinoma cells. J. Nanopart. Res. 2012, 14.
37. Markovic Z., Todorovic-Markovic B., Kleut D., Nikolic N., Vranjes-Djuric S., Misirkic M., Vucicevic L., Janjetovic K., Isakovic A., Harhaji L., Babic-Stojic B., Dramicanin M., Trajkovic V. The mechanism of cell-damaging reactive oxygen generation by colloidal fullerenes. Biomaterials 2007, 28:5437-5448.
38. Monteiro-Riviere N.A., Inman A.O., Zhang L.W. Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. Toxicol. Appl. Pharmacol. 2009, 234:222-235.
39. Montellano A., Da Ros T., Bianco A., Prato M. Fullerene C 60 as a multifunctional system for drug and gene delivery. Nanoscale 2011, 3:4035-4041.
40. Moustakas A., Heldin C.H. Dynamic control of TGF-β signaling and its links to the cytoskeleton. FEBS Lett. 2008, 582:2051-2065.
41. Nakagawa Y., Suzuki T., Ishii H., Nakae D., Ogata A. Cytotoxic effects of hydroxylated fullerenes on isolated rat hepatocytes via mitochondrial dysfunction. Arch. Toxicol. 2011, 85:1429-1440.
42. Nishizawa C., Hashimoto N., Yokoo S., Funakoshi-Tago M., Kasahara T., Takahashi K., Nakamura S., Mashino T. Pyrrolidinium-type fullerene derivative-induced apoptosis by the generation of reactive oxygen species in HL-60 cells. Free Radic. Res. 2009, 43:1240-1247.
43. Okamoto J., Mikami I., Tominaga Y., Kuchenbecker K.M., Lin Y.C., Bravo D.T., Clement G., Yagui-Beltran A., Ray M.R., Koizumi K., He B., Jablons D.M. Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. J. Thoracic Oncol. 2008, 3:1089-1095.
44. Schieke S.M., Phillips D., McCoy J.P., Aponte A.M., Shen R.-F., Balaban R.S., Finkel T. The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J. Biol. Chem. 2006, 281:27643-27652.
45. Shaw R.J., Bardeesy N., Manning B.D., Lopez L., Kosmatka M., DePinho R.A., Cantley L.C. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004, 6:91-99.
46. Soltoff S.P. Rottlerin: an inappropriate and ineffective inhibitor of PKCδ. Trends Pharmacol. Sci. 2007, 28:453-458.
47. Song K., Wang H., Krebs T.L., Danielpour D. Novel roles of Akt and mTOR in suppressing TGF-[beta]/ALK5-mediated Smad3 activation. EMBO J. 2006, 25:58-69.
48. 60 aggregates: more sensitive indication by apoptosis-related Bax translocation in cultured human cells. Environ. Sci. Technol. 2012, 46:3457-3464.
49. Ui M., Okada T., Hazeki K., Hazeki O. Wortmannin as a unique probe for an intracellular signalling protein, phosphoinositide 3-kinase. Trends Biochem. Sci. 1995, 20:303-307.
50. Vlahos C.J., Matter W.F., Hui K.Y., Brown R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 1994, 269:5241-5248.
51. Wang H., Radjendirane V., Wary K.K., Chakrabarty S. Transforming growth factor β regulates cell-cell adhesion through extracellular matrix remodeling and activation of focal adhesion kinase in human colon carcinoma Moser cells. Oncogene 2004, 23:5558-5561.
52. Wang H., Rajan S., Liu G., Chakrabarty S. Transforming growth factor β suppresses β-catenin/Wnt signaling and stimulates an adhesion response in human colon carcinoma cells in a Smad4/DPC4 independent manner. Cancer Lett. 2008, 264:281-287.
53. 60(Nd) nanoparticles enhance chemotherapeutic susceptibility of cancer cells by modulation of autophagy. Nanotechnology 2010, 21.
54. Weinbach E.C., Garbus J. Mechanism of action of reagents that uncouple oxidative phosphorylation. Nature 1969, 221:1016-1018.
55. White-Gilbertson S., Kurtz D.T., Voelkel-Johnson C. The role of protein synthesis in cell cycling and cancer. Mol. Oncol. 2009, 3:402-408.
56. Wörle-Knirsch J.M., Pulskamp K., Krug H.F. Oops they did it again! Carbon nanotubes hoax scientists in viability assays. Nano Lett. 2006, 6:1261-1268.
57. Yang J., Shamji A., Matchacheep S., Schreiber S.L. Identification of a small-molecule inhibitor of class Ia PI3Ks with cell-based screening. Chem. Biol. 2007, 14:371-377.
58. Zhang Y., Feng X.-H., Derynck R. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-[beta]-induced transcription. Nature 1998, 394:909-913.